A

AbbVie

Global biopharmaceutical company developing medicines

Executive Medical Director - Oncology Clinical Development, Solid Tumors

Full-TimeUpdated on 10/23/2026
$234k - $444k/yr+ Long-term incentive program
Senior
MD
Florham Park, NJ, USA
HybridOnsite Tuesday through Thursday each week.
Biology & Biotech

About the job

Requirements
  • A Medical Doctor (M.D.), Doctor of Osteopathy (D.O.), or non-U.S. equivalent of an M.D. degree with a relevant therapeutic specialty in an academic or hospital environment is required.
  • At least 5 years of clinical trial experience in the pharmaceutical industry, academia, or equivalent is required.
  • Ability to run a complex clinical research program independently is required.
  • Proven leadership skills and ability to bring out the best in others on a cross-functional global team, and ability to lead through influence, are required.
  • Ability to interact externally and internally to support a global scientific and business strategy is required.
  • Extensive knowledge of clinical trial methodology and regulatory and compliance requirements governing clinical trials, and experience in developing clinical strategy and designing study protocols, are required.
  • Excellent oral and written English communication skills are required.
  • Ability to exercise judgment, address complex problems, and create solutions for one or more projects is required.
Responsibilities
  • Lead the direction, planning, execution, and interpretation of clinical trials or research activities for one or more clinical development programs.
  • Participate in and potentially lead cross-functional teams to generate, deliver, and disseminate high-quality clinical data supporting product scientific and business strategy.
  • Lead and own the design and implementation of multiple clinical development programs, or one large, complex program, in support of the overall product development plan, based on medical and scientific principles, compliance and regulatory knowledge, knowledge of AbbVie's customers, markets, and business operations, and emerging issues.
  • Oversee project-related education of investigators, study-site personnel, and AbbVie study staff.
  • Lead clinical study teams; monitor study integrity; and review, interpret, and communicate accumulating molecule safety and efficacy data.
  • Partner with Clinical Operations to ensure agreed-upon study enrollment and timelines for key deliverables.
  • Assess and report serious adverse events under corporate policy and regulations for assigned protocols.
  • Own the design, analysis, interpretation, and reporting of scientific content for protocols, Investigator Brochures, Clinical Study Reports, regulatory submissions and responses, and other program documents.
  • Potentially oversee Medical and/or Scientific Directors and Clinical Scientists working on the same or related programs.
  • Potentially serve on or chair Clinical Strategy Teams and develop rigorous, cross-functionally aligned, vetted Clinical Development Plans that consider contingencies and alternative approaches.
  • As Clinical Strategy Team chair, potentially supervise matrix team members and represent Clinical Research on Asset Development Teams and Asset Development Team Leadership Boards, contributing clinical development and medical expertise.
  • Serve as an in-house clinical expert for one or more molecules and diseases in the therapeutic area, coordinating and leading relevant scientific and medical activities with internal stakeholders for ongoing projects.
  • Potentially participate in or lead clinical development contributions to due diligence or other business development activity.
  • As program needs require, partner with Discovery colleagues to design and implement translational strategies.
  • Act as clinical lead and actively solicit opinion-leader interactions related to disease areas; partner with Medical Affairs, Commercial, and other functions as needed and consistent with corporate policies to incorporate broad cross-functional perspectives into Clinical Development Plans and protocols.
  • Stay current with professional information and technology through conferences, medical literature, and other training.
  • Potentially represent AbbVie at key external meetings.
  • Understand regulatory requirements related to clinical studies and global drug development and comply with those requirements.
  • Serve as a clinical representative in key regulatory discussions.
  • Ensure adherence to Good Clinical Practices, pharmacovigilance standards, standard operating procedures, and other quality standards in research.
Desired Qualifications
  • Completion of a residency program is strongly preferred.
  • Completion of a subspecialty fellowship is desirable.
  • Seven years of clinical trial experience is preferred.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 23rd, 2026
ETFs net sell $42.1M of AbbVie as XLV leads $32.0M exit

Exchange-traded funds (ETFs) were net sellers of AbbVie shares for a second straight session, selling a net $42.1 million on October 21. Sellers moved larger sums even though more funds bought than sold: 24 ETFs added shares and 23 cut them. The Health Care Select Sector SPDR Fund led the selling with $32.0 million, followed by iShares Core S&P 500 ETF at $9.3 million and SPDR S&P 500 ETF Trust at $2.0 million. On October 20, ETFs sold a net $6.7 million, after three days of net buying. AbbVie has a market cap of $504.0 billion. Trailing 12-month revenue was $64.39 billion, up 10.3% over the past year.

Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.